Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Xenon Pharmaceuticals’s reported figures.
Plus components not separately reported this period.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
FAQ
- What is Xenon Pharmaceuticals's EBIT?
- Xenon Pharmaceuticals (XENE) reported EBIT of -$123.16M in Q2 2026.
- How has Xenon Pharmaceuticals's EBIT changed year-over-year?
- Xenon Pharmaceuticals's EBIT decreased by 30.7% year-over-year, from -$94.23M to -$123.16M.
- What is the long-term trend for Xenon Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's EBIT has grown at a 47.4% compound annual growth rate (CAGR), from -$78.99M to -$373.07M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Xenon Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude